Phase II trial of carboplatin plus oral etoposide for elderly patients with small-cell lung cancer

Authors
Matsui, K Masuda, N Fukuoka, M Yana, T Hirashima, T Komiya, T Kobayashi, M Kawahara, M Atagi, S Ogawara, M Negoro, S Kudoh, S Furuse, K
Citation
K. Matsui et al., Phase II trial of carboplatin plus oral etoposide for elderly patients with small-cell lung cancer, BR J CANC, 77(11), 1998, pp. 1961-1965
Citations number
31
Categorie Soggetti
Oncology,"Onconogenesis & Cancer Research
Journal title
BRITISH JOURNAL OF CANCER
ISSN journal
00070920 → ACNP
Volume
77
Issue
11
Year of publication
1998
Pages
1961 - 1965
Database
ISI
SICI code
0007-0920(199806)77:11<1961:PITOCP>2.0.ZU;2-P
Abstract
A phase II trial was conducted to evaluate the efficacy and toxicity of the Egorin's carboplatin dosing formula with 14-day oral etoposide in 38 elder ly patients with small-cell lung cancer (SCLC). The overall response rate w as 81%. Median survival times were 15.1 months for 16 limited-disease (LD) and 8.6 months for 22 extensive-disease (ED) patients. Myelosuppression was the principal side-effect. This regimen is an active regimen in the treatm ent of elderly SCLC patients.